1 completed, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow HAM: new trials by email Literature Review of HAM trials Research Report on HAM
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML CPI-613 + High Dose Cytarabine and Mitoxantrone, High Dose Cytarabine and Mitoxantrone, Mitoxantrone, Etoposide and Cytarabine - Relapsed/Refractory Acute Myeloid Leukemia | Phase 3 | Terminated | Cornerstone Pharmaceuticals | 200 | 2018-11-12 | 2023-02-08 |
| Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML HAM, LDAC and/or Mitoxantrone - Acute Myeloid Leukemia | Phase 3 | Completed | DKMS gemeinnützige GmbH | 281 | 2015-09-17 | 2024-01-19 |
Cornerstone Pharmaceuticals (1) · DKMS gemeinnützige GmbH (1)
Germany (2) · Australia (1) · Austria (1) · Belgium (1) · France (1) · Poland (1) · South Korea (1) · Spain (1) · United States (1)
Johannes Schetelig, Prof Dr med (1) · Jorge E Cortes, MD (1)
PMID 38583455, PMID 40454396, PMID 40737595
2014 (1)